Skip to main content
COGT
NASDAQ Life Sciences

Fairmount Funds Reduces Stake in Cogent Biosciences by $127.4 Million

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$39.53
Mkt Cap
$6.011B
52W Low
$3.72
52W High
$43.73
52W Position info
963% above low
Off High info
9.6% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

COGT has more than doubled off its 52-week low of $3.72.

Summary

Fairmount Funds Management LLC, a significant institutional investor, reported selling 3.5 million shares of Cogent Biosciences common stock for $127.4 million, reducing its ownership to 9.9%.


Key Events · Ownership and Investor Activity · COGT

  • Significant Share Sale

    Fairmount Funds Management LLC sold 3,500,000 shares of common stock in a block trade.

  • Transaction Value

    The shares were sold at $36.40 per share, totaling $127.4 million.

  • Reduced Ownership Stake

    Following the sale, Fairmount Funds Management LLC's beneficial ownership in Cogent Biosciences decreased to 9.9% of the outstanding common stock.


Analysis · COGT · Life Sciences

Fairmount Funds Management LLC, a major institutional holder, executed a substantial block trade, selling 3.5 million shares of Cogent Biosciences. This transaction, valued at $127.4 million, represents a notable reduction in their position, bringing their beneficial ownership down to 9.9% of the outstanding common stock. While institutional sales can occur for various reasons, a disposition of this magnitude by a significant shareholder could be interpreted as a signal of reduced conviction or a portfolio rebalancing. Investors should monitor future filings for further changes in institutional ownership.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COGT was trading at $39.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COGT - Latest Insights

COGT
Sep 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.50
Real-time Price: $32.48 info
Change: -$1.02 (-3%) info
Market Cap: $5.556B info
COGT
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.53
Real-time Price: $32.48 info
Change: -$9.05 (-22%) info
Market Cap: $5.556B info
COGT
Aug 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.55
Real-time Price: $32.48 info
Change: -$8.07 (-20%) info
Market Cap: $5.556B info
COGT
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $38.60
Real-time Price: $32.48 info
Change: -$6.12 (-16%) info
Market Cap: $5.556B info
COGT
May 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $34.91
Real-time Price: $32.48 info
Change: -$2.43 (-7%) info
Market Cap: $5.556B info